06 - Nicotine and Tobacco-merged

Nicotine & Indolamine Hallucinogens (LSD & Psilocybin)

Originated from North America, first utilized by indigenous peoples for medicinal purposes.
Became globally introduced following Columbus's arrival in 1492.
Smoking prevalence trends in Canada show both an increase in tobacco use followed by a decline due to awareness of health risks.

Historically used in various cultures for spiritual and religious purposes.
The counterculture movement of the 1960s popularized their recreational use.
Current research focuses on their potential therapeutic applications for mental health conditions like depression and PTSD.

Routes of Administration: Primarily through smoking or vaping, with absorption rates varying by method.
Absorption: 90% absorption via tobacco smoke, with peak effects occurring within 5-10 minutes.
Distribution: Rapidly distributed throughout the body, crossing the blood-brain barrier.
Metabolism: Metabolized largely in the liver via cytochrome P450 enzymes.
Elimination: Short half-life (~2 hours), requiring regular use for sustained effects.

Routes of Administration: Typically consumed orally (tablets, blotter paper) but can also be administered intranasally.
Absorption: Rapidly absorbed through the gastrointestinal tract when ingested, effects usually felt within 20-30 minutes.
Distribution: Highly water-soluble and distributes quickly to the brain.
Metabolism: Primarily metabolized in the liver, with active metabolites contributing to effects.
Elimination: Half-life of 3-6 hours; effects may last up to 12 hours.

Routes of Administration: Usually consumed orally, often in the form of dried mushrooms (Psilocybe species).
Absorption: Absorbed through the gastrointestinal tract; effects can begin within 20-40 minutes.
Distribution: Quickly distributed to the brain, where it acts on serotonin receptors.
Metabolism: Converted to psilocin in the body, which is responsible for psychoactive effects.
Elimination: Half-life of 1-3 hours.

Acts as a potent agonist at nicotinic acetylcholine receptors, leading to increased dopamine release, which plays a role in reinforcement and addiction.

Both drugs primarily act as agonists at serotonin 5-HT2A receptors, leading to alterations in perception, mood, and cognition.
They affect other neurotransmitter systems, contributing to their complex effects on consciousness.

Short-term: Increased heart rate and blood pressure, nausea.
Long-term: Increased risks of lung and oral cancers, respiratory and cardiovascular diseases; dependence and withdrawal symptoms.

Short-term: Anxiety, paranoia, and potential for 'bad trips' causing distressing hallucinations.
Long-term: Potential for persistent psychosis and hallucinogen persisting perception disorder (HPPD).

Short-term: Can cause anxiety, nausea, confusion, and perceptual disturbances.
Long-term: Risk of psychological distress, especially in individuals with a predisposition to mental health issues.

Can enhance attention, improve cognitive performance temporarily, but chronic use is linked to cognitive deficits over time.

May lead to altered states of consciousness, enhanced introspection, and creativity; however, they can impair judgment and behavior during their active periods.

Research into its use for cognitive enhancement, though health risks typically overshadow benefits.

Increasing interest in their therapeutic potential for mental health disorders, such as:
- PTSD
- Major depressive disorder (MDD)
- Anxiety disorders
Both have shown promise in clinical trials for improving psychological well-being and quality of life post-treatment.